GF
UTHR icon

Gerstein Fisher’s United Therapeutics UTHR Stock Holding History

Gerstein Fisher’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-6,980
Closed -$4.2M – 435
2013
Q4 		$4.2M Buy
+6,980
New +$629K 0.16% 153

Other funds holding UTHR

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Gerstein Fisher's UTHR Position: Q1 2014 in Review

Gerstein Fisher sold out of United Therapeutics (UTHR) in Q1 2014, closing a stake of 6,980 shares — an estimated $4.2M sold.

Gerstein Fisher first reported a position in UTHR in Q4 2013 and held it in 1 quarter. The position peaked at $4.2M in Q4 2013. 308 funds tracked by Wall St. Rank hold UTHR as of Q1 2014.

  • Gerstein Fisher reported no remaining United Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Gerstein Fisher sold 6,980 United Therapeutics shares in Q1 2014, an estimated $4.2M.
  • Gerstein Fisher first reported a position in United Therapeutics in Q4 2013 and held it in 1 quarter.
  • Gerstein Fisher's United Therapeutics position peaked at $4.2M in Q4 2013.
  • 308 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2014.

Based on Gerstein Fisher's 13F filing for Q1 2014, filed 15 May 2014.